Evidence map›Paper›PMID 32806582›Full record

ArticleInternational journal of molecular sciences2020

Neuroimmune Response in Natural Preclinical Scrapie after Dexamethasone Treatment.

Isabel M Guijarro, Moisés Garcés, Belén Marín, Alicia Otero, Tomás Barrio, Juan J Badiola, Marta Monzón

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Astrocyte in prion disease: a double-edged sword.Neural regeneration research · 2022
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Isabel M GuijarroResearch Centre for Encephalopathies and Transmissible Emerging Diseases - Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain.
Moisés GarcésResearch Centre for Encephalopathies and Transmissible Emerging Diseases - Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain.
Belén MarínResearch Centre for Encephalopathies and Transmissible Emerging Diseases - Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain.
Alicia OteroResearch Centre for Encephalopathies and Transmissible Emerging Diseases - Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain.
Tomás BarrioResearch Centre for Encephalopathies and Transmissible Emerging Diseases - Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain.
Juan J BadiolaResearch Centre for Encephalopathies and Transmissible Emerging Diseases - Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain.
Marta MonzónResearch Centre for Encephalopathies and Transmissible Emerging Diseases - Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain.ORCID 0000-0002-2787-9671
Universidad de Zaragoza · ES

Funding

European Regional Development Fund EFA 148/16 REDPRIONMinisterio de Educación, Cultura y Deporte FPU 15/03524
6 · The paper itself

Abstract

A recently published report on chronic dexamethasone treatment for natural scrapie supported the hypothesis of the potential failure of astroglia in the advanced stage of disease. Herein, we aimed to extend the aforementioned study on the effect of this anti-inflammatory therapy to the initial phase of scrapie, with the aim of elucidating the natural neuroinflammatory process occurring in this neurodegenerative disorder. The administration of this glucocorticoid resulted in an outstanding reduction in vacuolation and aberrant protein deposition (nearly null), and an increase in glial activation. Furthermore, evident suppression of IL-1R and IL-6 and the exacerbation of IL-1α, IL-2R, IL-10R and IFNγR were also demonstrated. Consequently, the early stage of the disease is characterized by an intact neuroglial response similar to that of healthy individuals attempting to re-establish homeostasis. A complex network of neuroinflammatory markers is involved from the very early stages of this prion disease, which probably becomes impaired in the more advanced stages. The in vivo animal model used herein provides essential observations on the pathogenesis of natural scrapie, as well as the possibility of establishing neuroglia as potential target cells for anti-inflammatory therapy.

Indexed as

AnimalsAstrocytesBrainCytokinesDexamethasoneFemaleGliosisMicrogliaScrapieSheepStatistics as TopicCytokinesDexamethasonecytokinedexamethasoneglucocorticoidsneuroglianeuroinflammationpreclinical stageprion diseasesscrapie

Identifiers

PMID32806582
PMCPMC7460817
OpenAlexW3048498384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.